Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Medicare Beneficiaries With Advanced Lung Cancer Experience Diverse Patterns Of Care From Diagnosis To Death.

Schuler MS, Joyce NR, Huskamp HA, Lamont EB, Hatfield LA.

Health Aff (Millwood). 2017 Jul 1;36(7):1193-1200. doi: 10.1377/hlthaff.2017.0448.

2.

Use of High-cost Systemic Treatments in Elderly mCRC Patients.

Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB.

Med Care. 2017 Jan;55(1):86-87. No abstract available.

3.

Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.

Hatfield LA, Huskamp HA, Lamont EB.

J Oncol Pract. 2016 Jul;12(7):666-73. doi: 10.1200/JOP.2016.012492. Epub 2016 Jun 28.

4.

Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients.

Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB.

Med Care. 2016 May;54(5):490-7. doi: 10.1097/MLR.0000000000000510.

PMID:
26900834
5.

Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer.

Kehl KL, Lamont EB, McNeil BJ, Bozeman SR, Kelley MJ, Keating NL.

J Geriatr Oncol. 2015 May;6(3):202-10. doi: 10.1016/j.jgo.2015.01.005. Epub 2015 Feb 3.

PMID:
25662785
6.

Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2014 Nov 27;107(1):336. doi: 10.1093/jnci/dju336. Print 2015 Jan.

7.

Genotyping lung cancer is an investment in the future.

Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS.

J Clin Oncol. 2014 Nov 1;32(31):3576-7. doi: 10.1200/JCO.2014.56.6430. Epub 2014 Sep 8. No abstract available.

PMID:
25199750
8.

Elderly breast and colorectal cancer patients' clinical course: patient and contextual influences.

Lamont EB, Zaslavsky AM, Subramanian SV, Meilleur AE, He Y, Landrum MB.

Med Care. 2014 Sep;52(9):809-17. doi: 10.1097/MLR.0000000000000180.

9.

Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).

Lamont EB, Yu M, He Y, Saltz L, Muss H, Zaslavsky AM; Alliance for Clinical Trials in Oncology.

J Geriatr Oncol. 2014 Jul;5(3):230-7. doi: 10.1016/j.jgo.2014.02.001. Epub 2014 Mar 1.

10.

Rural residence and cancer outcomes in the United States: issues and challenges.

Meilleur A, Subramanian SV, Plascak JJ, Fisher JL, Paskett ED, Lamont EB.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1657-67. doi: 10.1158/1055-9965.EPI-13-0404. Review.

11.

Tumor boards and the quality of cancer care.

Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ.

J Natl Cancer Inst. 2013 Jan 16;105(2):113-21. doi: 10.1093/jnci/djs502. Epub 2012 Dec 28.

12.

Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy.

Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB.

Cancer. 2013 Feb 1;119(3):691-9. doi: 10.1002/cncr.27787. Epub 2012 Sep 25.

13.

Do socially deprived urban areas have lesser supplies of cancer care services?

Lamont EB, He Y, Subramanian SV, Zaslavsky AM.

J Clin Oncol. 2012 Sep 10;30(26):3250-7. doi: 10.1200/JCO.2011.40.4228. Epub 2012 Aug 6. Erratum in: J Clin Oncol. 2013 Jun 20;31(18):2364-5.

14.

Most colorectal cancer survivors live a large proportion of their remaining life in good health.

Soerjomataram I, Thong MS, Ezzati M, Lamont EB, Nusselder WJ, van de Poll-Franse LV.

Cancer Causes Control. 2012 Sep;23(9):1421-8. doi: 10.1007/s10552-012-0010-2. Epub 2012 Jun 26.

15.

Area-level variations in cancer care and outcomes.

Keating NL, Landrum MB, Lamont EB, Bozeman SR, McNeil BJ.

Med Care. 2012 May;50(5):366-73. doi: 10.1097/MLR.0b013e31824d74c0.

PMID:
22437623
16.

Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.

Lamont EB, Lan L.

Med Care. 2014 Mar;52(3):e15-20. doi: 10.1097/MLR.0b013e31824e342f.

17.

Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare.

Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, Shulman L, Brown JR, Earle CC, Rabin M, McNeil BJ.

J Clin Oncol. 2012 Apr 1;30(10):1072-9. doi: 10.1200/JCO.2011.35.6758. Epub 2012 Mar 5.

18.

Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.

Nambudiri VE, Landrum MB, Lamont EB, McNeil BJ, Bozeman SR, Freedland SJ, Keating NL.

Urology. 2012 Mar;79(3):537-45. doi: 10.1016/j.urology.2011.11.013. Epub 2012 Jan 13.

PMID:
22245306
19.

Location of cancer surgery for older veterans with cancer.

Kouri EM, Landrum MB, Lamont EB, Bozeman S, McNeil BJ, Keating NL.

Health Serv Res. 2012 Apr;47(2):783-93. doi: 10.1111/j.1475-6773.2011.01327.x. Epub 2011 Sep 23.

20.

Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration.

Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ.

Cancer. 2012 Jul 1;118(13):3345-55. doi: 10.1002/cncr.26628. Epub 2011 Nov 9.

21.

Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer.

Gray SW, Landrum MB, Lamont EB, McNeil BJ, Jaklitsch MT, Keating NL.

Cancer. 2012 Mar 1;118(5):1404-11. doi: 10.1002/cncr.26363. Epub 2011 Jul 28.

22.

Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study.

Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M, McNeil BJ.

Ann Intern Med. 2011 Jun 7;154(11):727-36. doi: 10.7326/0003-4819-154-11-201106070-00004.

PMID:
21646556
23.

End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector.

Keating NL, Landrum MB, Lamont EB, Earle CC, Bozeman SR, McNeil BJ.

Cancer. 2010 Aug 1;116(15):3732-9. doi: 10.1002/cncr.25077.

24.

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL.

Urology. 2010 Mar;75(3):642-7. doi: 10.1016/j.urology.2009.08.008. Epub 2009 Dec 4.

PMID:
19962733
25.

Differences in clinical trial patient attributes and outcomes according to enrollment setting.

Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, Clamon GH, Elias AD, McClay EF, Vokes EE, McNeil BJ.

J Clin Oncol. 2010 Jan 10;28(2):215-21. doi: 10.1200/JCO.2008.21.3652. Epub 2009 Nov 23.

26.

Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives.

Dow LA, Matsuyama RK, Ramakrishnan V, Kuhn L, Lamont EB, Lyckholm L, Smith TJ.

J Clin Oncol. 2010 Jan 10;28(2):299-304. doi: 10.1200/JCO.2009.24.6397. Epub 2009 Nov 23.

27.

Utility of administrative claims data for the study of brain metastases: a validation study.

Eichler AF, Lamont EB.

J Neurooncol. 2009 Dec;95(3):427-431. doi: 10.1007/s11060-009-9943-z. Epub 2009 Jun 27.

PMID:
19562256
28.
29.

Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study.

Lamont EB, Dias LE.

Cancer J. 2008 Jul-Aug;14(4):276-7. doi: 10.1097/PPO.0b013e318182ee67. No abstract available.

30.

Evaluation of trends in the cost of initial cancer treatment.

Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML.

J Natl Cancer Inst. 2008 Jun 18;100(12):888-97. doi: 10.1093/jnci/djn175. Epub 2008 Jun 10.

31.

Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma.

Lamont EB, Cavaghan MK, Brockstein BE.

Sarcoma. 1999;3(2):95-9. doi: 10.1080/13577149977712.

32.

Cost of care for elderly cancer patients in the United States.

Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML.

J Natl Cancer Inst. 2008 May 7;100(9):630-41. doi: 10.1093/jnci/djn103. Epub 2008 Apr 29.

PMID:
18445825
33.

Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA; Cancer and Leukemia Group B.

Med Care. 2008 Mar;46(3):303-8. doi: 10.1097/MLR.0b013e31815cecc3.

34.

NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect?

Lamont EB, Dias LE, Lauderdale DS.

J Gen Intern Med. 2007 Aug;22(8):1166-71. Epub 2007 Jun 19.

35.

Patient time costs associated with cancer care.

Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, Warren JL.

J Natl Cancer Inst. 2007 Jan 3;99(1):14-23.

PMID:
17202109
36.

Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA; Cancer and Leukemia Group B.

J Natl Cancer Inst. 2006 Sep 20;98(18):1335-8. Erratum in: J Natl Cancer Inst. 2006 Nov 1;98(21):1584. J Natl Cancer Inst. 2008 Jan 2;100(1):70.

37.

Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments.

Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3601s-5s. Review.

38.

A demographic and prognostic approach to defining the end of life.

Lamont EB.

J Palliat Med. 2005;8 Suppl 1:S12-21. Review.

PMID:
16499460
40.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA.

J Natl Cancer Inst. 2005 Jul 20;97(14):1080-3.

PMID:
16030306
41.

Paradoxes in cancer patients' advance care planning.

Lamont EB, Siegler M.

J Palliat Med. 2000 Spring;3(1):27-35.

PMID:
15859719
42.
43.

Low risk of hip fracture among elderly breast cancer survivors.

Lamont EB, Lauderdale DS.

Ann Epidemiol. 2003 Nov;13(10):698-703.

PMID:
14599734
44.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE.

J Natl Cancer Inst. 2003 Sep 17;95(18):1370-5.

PMID:
13130112
45.
46.

Favorable cardiac risk among elderly breast carcinoma survivors.

Lamont EB, Christakis NA, Lauderdale DS.

Cancer. 2003 Jul 1;98(1):2-10.

48.
49.

Chemotherapy in the management of squamous-cell carcinoma of the head and neck.

Lamont EB, Vokes EE.

Lancet Oncol. 2001 May;2(5):261-9. Review.

PMID:
11905780
50.

Construct validity of medicare chemotherapy claims: the case of 5FU.

Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA.

Med Care. 2002 Mar;40(3):201-11.

PMID:
11880793

Supplemental Content

Loading ...
Support Center